Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

seizures/cancro

Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 40 risultati

Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and that such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or

Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have

Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have

Use of isatin derivatives as ion channel activating agents

Solo gli utenti registrati possono tradurre articoli
Entra registrati
TECHNICAL FIELD The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK.sub.Ca and IK.sub.Ca channels. In further aspects, the present invention relates to the

Compositions and methods for the treatment of severe pain

Solo gli utenti registrati possono tradurre articoli
Entra registrati
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

Non-natural galanin receptor ligands

Solo gli utenti registrati possono tradurre articoli
Entra registrati
The present invention relates to non-natural galanin receptor ligands which can function as agonists and antagonists of galanin and can be used to treat diseases or conditions in which galanin plays a role. BACKGROUND OF THE INVENTION Galanin.sup.1 is a 29/30 amino acid long neuroendocrine peptide

Therapeutic use of compounds

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent

Adenosine receptor agonists, partial agonists, and antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the

Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their

Bumetanide analogs, compositions and methods of use

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates

Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This application is the United States national stage of International Application No. PCT/EP01/15289, filed Dec. 21, 2001, which was published under PCT Article 21(2) in English as International Publication No. WO 02/051438, and which claims benefit of European Patent Application No. 00128356.3

Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND TO THE INVENTION The present invention is generally in the field of therapeutic formulations for delivering gamma-hydroxybutyrate. Gamma-hydroxybutyrate ("GHB") is a naturally occurring substance that is widely distributed in the mammalian body, being present, for example, in the brain,

Bisarylamines as potassium channel openers

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION This invention relates to the use of certain bisarylamines as potassium channel openers and to the treatment of diseases modulated by potassium channel opening. Additionally, this invention relates to novel compounds that are useful as potassium channel openers. BACKGROUND OF

Heterocycles as potassium channel modulators

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride, into and out of cells. These channels are present in all human cells and affect such processes as nerve transmission, muscle contraction and cellular

Heterocycles as potassium channel modulators

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride, into and out of cells. These channels are present in all human cells and affect such processes as nerve transmission, muscle contraction and cellular
Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge